Malignant peripheral nerve sheath tumors: a report from Children’s Oncology Group study ARST0332
Timestops (3)
Tools Used
Topic Overview
Key Takeaways
- Surgical resection remains the primary determinant of survival in pediatric malignant peripheral nerve sheath tumors.
- Female sex, absence of metastatic disease, and low-risk classification predict improved outcomes in MPNST patients.
- Neoadjuvant chemoradiation response (23% response rate) does not correlate with post-resection survival outcomes.
- Complete resection should be pursued even after good neoadjuvant therapy response, as it drives survival benefit.
- Risk-adapted treatment stratification (observation to neoadjuvant chemoradiation) guides management in pediatric MPNST.
Keywords
Hashtags
Transcript
Is there a role for chemo radiation in peripheral nerve sheath tumors, or is excision all that is needed? I'm Jill Knerath with Stay Current MD, and this is an article you should know. In 2025, the Children's Oncology Group published a prospective trial in the Journal of the National Cancer Institute. They explored treatments and outcomes for patients with these rare tumors. So what did they do for these patients? Patients were assigned to 4 groups observation, adjuvant radiation. Adjuvant chemo radiation and neoadjuvant chemo radiation. What were the outcomes? Overall results confirmed that resection has a major influence on survival for these patients. Female patients, patients without metastatic disease, and low-risk patients also had improved outcomes. In patients receiving neoadjuvant therapy, 23% showed a response, 45% were stable, and 32% had progressive disease. Of these patients that went on to have their resection. There was no difference in survival based on the response to neoadjuvant therapy. Overall, this study confirms that resection should be done for these patients whenever possible, even if they show a good response to chemo radiation.